Dawrui Pharmaceuticals: Wang Qingtai and Cao Xiaobing have issued a partial tender offer to acquire 19.44 million shares, accounting for 24.30% of the total share capital.

Doray Pharmaceuticals announced that on October 13, 2025, and November 11, 2025, Tibet Jiakang Era Technology Development Co., Ltd. and its concerted action person signed the "Stock Transfer Agreement" and the "Supplementary Agreement to the Stock Transfer Agreement" with Wang Qingtai, Cui Zihao, and Cao Xiaobing. Tibet Jiakang and Zhoushan Qingchang plan to transfer a total of 23.68 million unrestricted circulating shares of the company to Wang Qingtai and its concerted action persons Cui Zihao and Cao Xiaobing through agreement transfer. Meanwhile, Wang Qingtai and Cao Xiaobing plan to further increase their stake in the listed company through partial tender offer, with the quantity of shares for tender offer being 19.44 million shares.